As an accountant, this is what I see:
December Quarter
Revenue 23,151
Sept Deferred Product Royalty 319,271 This relates to September product sales.
Total Income Received December 342,422
September Quarter
Product Royalty 338,963
Total Product Royalty Received 6 Mths 681,385
R & D Income 842,824
Total Six Months Income 1,542,209
The product royalty mainly relates to SK II (partially launched in the middle of the September quarter) with a small contribution from Olay, which was just getting started during the December quarter.
The December quarter royalty cheque should be received mid Feb (6 weeks after the end of the Dec quarter) and banked a week later. Skillful HC researchers, who are much appreciated, lead us to believe that it is expected to be a good result.
This is an encouraging report. My opinion only.
- Forums
- ASX - By Stock
- Encouraging Report
WFL
wellfully limited
Add to My Watchlist
0.00%
!
0.3¢

As an accountant, this is what I see: December Quarter Revenue...
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online